Strategies for the Reduction or Discontinuation of Opioids: Guidelines
Authors: Charlotte Wells, Caitlyn Ford


Acknowledgments:

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Research Questions

1. What are the evidence-based guidelines regarding tapering strategies for the reduction or discontinuation of opioids?
2. What are the evidence-based guidelines regarding switching or crossover strategies for the reduction or discontinuation of opioids?

Key Findings

Six evidence-based guidelines were identified regarding tapering, rotating, switching, or crossover strategies for the reduction or discontinuation of opioids.

Methods

A limited literature search was conducted on key resources including PubMed, Ovid Medline, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval health technology assessments, systematic reviews, meta-analyses, and guidelines. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2012 and March 23, 2017. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients with chronic, non-cancer pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention</td>
<td>Methods to taper/rotate/switch/crossover opioids</td>
</tr>
<tr>
<td>Comparator</td>
<td>Q1-2: No comparator</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Q1-2: Guidelines</td>
</tr>
<tr>
<td>Study Designs</td>
<td>Health technology assessments, systematic reviews, meta-analyses, evidence-based guidelines</td>
</tr>
</tbody>
</table>
Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Normally, health technology assessment reports, systematic reviews, and meta-analyses are presented first; however, in reports where guidelines are primarily sought the aforementioned evidence types are presented in the appendix.

Six evidence-based guidelines were identified regarding tapering, rotating, switching, or crossover strategies for the reduction or discontinuation of opioids.

Additional references of potential interest, along with the health technology assessment reports, systematic reviews, and meta-analyses, are provided in the appendix.

Overall Summary of Findings

Six evidence-based guidelines were identified regarding tapering, rotating, switching, or crossover strategies for the reduction or discontinuation of opioids. Three guidelines discuss the treatment and management of opioid use disorders. It is recommended to treat patients with individualized treatment plans that suit their specific needs.

One set of guidelines from the British Columbia Centre on Substance Use focuses on the clinical management of opioid use disorder and recommends against rapid tapering (over a time period of less than 1 week) for inpatients using methadone or buprenorphine/naloxone. If a patient wishes to avoid long term opioid agonist treatment, supervised, slow (over a time period of more than 1 month) outpatient opioid agonist taper is recommended over a rapid taper. These guidelines also suggest that oral naltrexone can be used as an adjunct therapy after a patient has ceased opioid use. The best clinical judgment should be used when treating individuals with opioid use disorder and opioid agonist tapers should only be used if the patient appears to have a high chance of a successful recovery with no long term agonist treatment.

The second guideline compared the effectiveness of abstinence-only treatment, buprenorphine-naloxone maintenance, and methadone maintenance; reporting a substantial advantage of methadone treatment or buprenorphine-naloxone treatment over abstinence. The authors recommend that individual patient characteristics should be taken into account when deciding on a treatment plan; however, either buprenorphine-naloxone maintenance or methadone maintenance should definitely be chosen over abstinence-only treatment. If withdrawal, opioid use, or cravings are persistent in patients who are on the appropriate buprenorphine-naloxone dose, patients should be switched to methadone quickly.

The Centers for Disease Control and Prevention guidelines for prescribing opioids for chronic pain that is non-cancer and non-palliative related recommend that, prior to initiation of an opioid treatment strategy, the discontinuation strategy for opioids should be considered and discussed. Evidence-based treatment should be offered to individuals with opioid use disorder, such as medication assisted treatment with buprenorphine or methadone.

The Institute for Clinical Systems Improvement guideline on opioid management recommends that if switching opioid types, opioid conversion tables should only be used as guidance. They also recommend that the doses of the new opioid be reduced by 50% of the previous daily morphine milligram equivalents dosage and subsequently titrated until
analgesia is achieved. When discontinuing opioids via a tapering strategy, the strategy should be individualized to the specific patient, with the option of additional treatment options and frequent follow up. They additionally recommend that any patients on chronic opioid treatment should be offered the option to initiate a tapering strategy for their opioid use every six months.

For initiation of methadone with the intention of switching from another opioid, the individual patient should be closely monitored and the treatment plan should be individualized based on the patient’s treatment indication. The guideline also recommends that when methadone is introduced, it should be initiated at low dose and titrated slowly.

Finally, the Agency for Healthcare Research and Quality guideline for pain treatment using opioids in injured workers recommends that, in most cases, it is advised to taper off opioids entirely. For workers not on a chronic high opioid dose who are in a community setting, a gradual taper of approximately 10% per week is recommended. Although not a requirement, the availability and addition of adjuvant therapies such as psychological treatment and cognitive behavioural therapy may be helpful in tapering. In an intensive setting (either for patients who failed tapering in a community setting or for those who are at a high risk of failure), a pain management specialist, structured intensive multidisciplinary program (SIMP) provider, or addiction medicine specialist should be consulted.

References Summarized

Guidelines and Recommendations


   See: Summary of Recommendations, pages 12-13
   Expert guideline, page 33

   PubMed: PM28292795

   PubMed: PM26977696


   See: 13.7 Opioid Rotation and Conversion
   13.10. Offer Discontinuation of Opioids or Taper at Intervals of Six Months, pages 77-80
See: Initiation of methadone

See: Discontinuing COT, page 6
Appendix — Further Information

Previous CADTH Reports


Systematic Reviews and Meta-analyses


See: Key Question 3. Dosing Strategies


Alternate Comparator


Alternate Interventions


Alternate Outcomes


Clinical Practice Guidelines – Uncertain Methodology


See: “RACGP recommendations for tapering opioids”


Review Articles


Additional References
